Miller A M
Department of Medicine, College of Medicine, University of Florida, Gainesville.
Semin Oncol. 1993 Oct;20(5 Suppl 6):88-95.
The availability of recombinant human hematopoietic growth factors (rhHGFs) for clinical use has the potential to significantly decrease the morbidity and cost of autologous bone marrow transplantation (ABMT) and to make this therapeutic modality available to a broader patient population. Three rhHGFs currently have Food and Drug Administration-approved indications, although only one has a specific indication for ABMT. Recombinant human granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor have been used in several trials of ABMT. Recombinant human erythropoietin is less well studied to date in the setting of ABMT. Several investigational rhHGFs, including interleukin-3, -6, and -11, PIXY 321 (a granulocyte-macrophage colony-stimulating factor/interleukin-3 hybrid), and kit ligand (also known as "stem cell factor"), have the potential for affecting multiple lineages.
临床可用的重组人造血生长因子（rhHGFs）有可能显著降低自体骨髓移植（ABMT）的发病率和成本，并使这种治疗方式适用于更广泛的患者群体。目前有三种rhHGFs获得了美国食品药品监督管理局批准的适应证，尽管只有一种有ABMT的特定适应证。重组人粒细胞巨噬细胞集落刺激因子和粒细胞集落刺激因子已用于多项ABMT试验。重组人促红细胞生成素在ABMT背景下的研究至今较少。几种研究性rhHGFs，包括白细胞介素-3、-6和-11、PIXY 321（一种粒细胞巨噬细胞集落刺激因子/白细胞介素-3融合蛋白）和kit配体（也称为“干细胞因子”），有可能影响多个谱系。
